“There will be epidemics...”

EBOLA: WORLD GOES ON RED ALERT

- Spread of Spanish Flu Menaces War Production
- Ebola Out of Control
- Death Toll Growing as Influenza Claims Many More Victims
- Officials: Texas Sees Growing Number of Typhus Cases
- Success in Tests of Yellow Fever Serum Reported
- FDA Busts Fake Malaria Medicines

Six Dead, 17 Sick From Drug-Resistant TB

Panic as 1,500 Die of Malaria

New Hope for AIDS Drug

DIPHTHERIA: Why Is It Back?

Malaria Cases on the Rise in Last 3 Years

ASTMH Annual Meeting Canceled Due to Spanish Flu Outbreak

Charity to Help Fight Malaria in Africa

Dengue Dengue EVERYWHERE

African Countries to Plot New Malaria Vaccine

Zika Spreads Worldwide

Island Declares State of Emergency Over Zika Virus, Dengue Fever Outbreak

An American Plague: Yellow Fever Epidemic of 1793

 Been to an Ebola-affected country? Stay away from ASTMH meeting, Louisiana says

DENGUE: Why Is It Back?

New Hope for AIDS Drug

Malaria Cases on the Rise in Last 3 Years

ASTMH Annual Meeting Canceled Due to Spanish Flu Outbreak
predicting “all-cause” febrile mortality in Ugandan children (AUROC 0.88, 95% CI 0.84-0.92, negative predictive value [NPV] 99.0%) and Tanzanian adults (AUROC 0.87, 95% CI, NPV 97.9%). STREM1 displayed non-inferior performance to established clinical disease severity scores (e.g. LODS: AUROC 0.90 95% CI 0.87-0.93, NPV 99.0%; qSOFA: 0.79, 95% CI 0.72-0.87, NPV 97.0%). Combinatorial models adding STREM1 to either LODS or qSOFA significantly improved their predictive accuracy in both the pediatric (AUROC 0.93, 95% CI 0.90-0.96, NPV 99.5%) and adult (AUROC 0.91, 95% CI 0.88-0.94, NPV 99.7%) cohorts. These data indicate that measuring STREM1 at clinical presentation, especially when combined with easy-to-measure clinical severity scores, can reliably identify febrile individuals at risk of death. Implementation of biomarker-based algorithms using point-of-care tests could improve the recognition, triage, and outcome of patients with life-threatening infections.

677

**CUTANEOUS LARVA MIGRANS IN RETURNED CANADIAN TRAVELERS TO THE CARIBBEAN: SURVEILLANCE REPORT FROM CANTRAVNET, JANUARY 2009 — MARCH 2018**

Andrea K. Boggild1, Jennifer Geduld2, Michael D. Libman3, Cedric P. Yansouni4, Anne E. McCarthy5, Jan Hajek1, Wayne Ghesquiere1, Yazdan Mirzanejad6, Katherine Plewes1, Jean Vincelette7, Susan Kuhn8, Pierre J. Plourde6, Christina Greenaway9, Sumontra Chakrabarti1, Kevin L. Schwartz1, Kevin C. Kain1

1University of Toronto, Toronto, ON, Canada, 2Public Health Agency of Canada, Ottawa, ON, Canada, 3McGill University, Montreal, QC, Canada, 4University of Ottawa, Ottawa, ON, Canada, 5University of British Columbia, Vancouver, BC, Canada, 6University of Montreal, Montreal, QC, Canada, 7University of Calgary, Calgary, AB, Canada, 8University of Manitoba, Winnipeg, MB, Canada

Cutaneous larva migrans (CLM) is one of the most common dermatoses with which travelers to the tropics return. We examined the demographic and travel correlates of Canadian travelers returning from the Caribbean with CLM over a 10-year period to illuminate the recent emergence of this disease in our traveling population. Data on all returned Canadian travelers presenting to a CanTravNet site between January 2009 and March 2018 who were diagnosed with CLM acquired in the Caribbean were analyzed. Of 22,169 travelers in the CanTravNet database over the enrolment period, 299 (1.3%) returned from the Caribbean with CLM. Median age of the returned travelers with CLM was 34 years (range 1 - 73 years), with males accounting for 41% of cases (n=123), and females 59% (n=176). Ninety-five percent (n=284) traveled for tourism. Jamaica was the most well-represented source country, accounting for 188 cases (63%), followed by Barbados (n=27, 9%), Dominican Republic (n=25, 8%), Cuba (n=21, 7%), and Saint Lucia (n=11, 4%). In total, 17 different source countries in the Caribbean were represented. Over the first 10-weeks of 2018, 48 travelers with CLM from the Caribbean were evaluated at CanTravNet sites, which represents a 6-fold average increase in cases during those same first 10-weeks in each of the 5 prior years (average 8 cases during the first 10-weeks of each year prior to 2018). Cases in 2018 have been imported predominantly from Jamaica (n=27, 56%), Dominican Republic (n=13, 27%), and Barbados (n=2, 4%), with 1 case (2%) imported from each of Cayman Islands, Cuba, Guadeloupe, Martinique, Saint Lucia, and Saint Martin. Age, sex, and purpose of travel distributions were similar across years. We have documented a large increase in imported cases of CLM originating in the Caribbean in the year 2018, though have not noted any demographic or travel-related aberrations in our returned traveler population to explain this phenomenon.

678

**ANTIBIOTIC MANAGEMENT OF MODERATE-TO-SEVERE DIARRHEA MAY REDUCE RISK OF LINEAR GROWTH FALTERING IN CHILDREN: A SECONDARY ANALYSIS OF GEMS CASES**

Rebecca Brander1, Judd Watson1, Patricia Pavlinac1, Grace John-Stewart1, Abu Faruque2, Anita Zaidi3, Dipika Sur4, Samba Sow5, M Johangir Hossain6, Pedro Alonso7, Robert Breiman8, Diliruba Nasrin9, James Nataro10, Myron Levine6, Karen Kotloff6

1University of Washington, Seattle, WA, United States, 2International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh, 3Aga Khan University, Karachi, Pakistan, 4National Institute of Cholera and Enteric Diseases, Kolkata, India, 5Centre for le Développement des Vaccines, Bamako, Mali, 6Medical Research Council Unit, Fajara, Gambia, 7Centro de Investigacao em Saude da Manhica, Maputo, Mozambique, 8Centers for Disease Control and Prevention, Nairobi, Kenya, 9University of Maryland, Baltimore, MD, United States, 10University of Virginia, Charlottesville, VA, United States

Children with moderate-to-severe diarrhea (MSD) are at particularly high risk of linear growth failure and associated negative health outcomes. However, little is known about whether antibiotic treatment of MSD may protect against linear growth faltering. Using previously collected data from the Global Enterics Multicenter Study (GEMS) of children 0-59 months old with MSD in 7 low- and middle-income countries (LMICs), we conducted a retrospective cohort analysis to assess whether children with MSD who were treated with antibiotics had a lower risk of linear growth faltering in the 60-90 days following the episode. We used relative risk (RR) regression to evaluate loss of ≥1 length/height-for-age z-score [LAZ/HAZ] between enrollment and follow up, and linear regression to assess change in LAZ/HAZ, with propensity score adjustment for variables associated with antibiotic treatment. Of 7659 surviving MSD cases, mean LAZ/HAZ loss during follow up was 0.13, and 3% lost ≥1 LAZ/HAZ. Antibiotics were provided to 81% at presentation. Factors associated with antibiotic treatment included young age, nutritional status, hospitalization, GEMS site, and presence of fever, vomiting, or dysentery. After propensity score adjustment, children provided with antibiotics had a 41% lower risk of losing ≥1 LAZ/HAZ than those who received none (adjusted RR: 0.59; 95% confidence interval [CI]: 0.42, 0.82). Children provided antibiotics in the health center gained 0.06 LAZ/HAZ more than those who were not (95% CI: 0.03, 0.09). Among children ≤ 23 months, those who received antibiotics were less likely to lose ≥1 LAZ/HAZ (aRR: 0.67, 95% CI: 0.48, 0.94), and gained 0.03 LAZ/HAZ more than those who received no antibiotics (95% CI: -0.004, 0.07). Antibiotic treatment of MSD may preserve linear growth in young children in LMICs. Ongoing randomized trials will provide further evidence to evaluate the effectiveness of antibiotics in preventing linear growth faltering in this population. However, any potential benefit of antibiotic management of MSD must be weighed cautiously against negative consequences including antibiotic resistance and microbiome disruption.

679

**CLINICAL FEATURES AND OUTCOME OF NEONATAL DENGUE AT THE CHILDREN'S HOSPITAL 1, HO CHI MINH, VIETNAM**

Tuan M. Nguyen

Children’s Hospital 1, Ho Chi Minh, Vietnam

Vertical transmission of dengue, a life-threatening disease transmitted by Aedes mosquitoes, has been reported in a few case reports. In this context, we tried to determine the clinical features and outcomes of neonatal dengue. We conducted a prospective study on 32 neonates with laboratory-confirmed dengue by positive for either NS1 antigen rapid test or IgM antibody with MAC-ELISA, who were hospitalized at the Children's Hospital 1, Ho Chi Minh, Vietnam from January 2010 to December 2016. Diagnosis of dengue was defined according to the World